Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B1ec0872d22fd3a9a02e6b6ff71a049e0> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B1ec0872d22fd3a9a02e6b6ff71a049e0 NCIT_P378 "NCI" @default.
- B1ec0872d22fd3a9a02e6b6ff71a049e0 type Axiom @default.
- B1ec0872d22fd3a9a02e6b6ff71a049e0 annotatedProperty IAO_0000115 @default.
- B1ec0872d22fd3a9a02e6b6ff71a049e0 annotatedSource NCIT_C175088 @default.
- B1ec0872d22fd3a9a02e6b6ff71a049e0 annotatedTarget "The phosphate salt form of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Upon administration, infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of angiogenesis and cell proliferation, and the induction of cell death in tumors with activating FGFR amplifications, mutations, or fusions. FGFRs are a family of receptor tyrosine kinases that are involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival. Activating FGFR amplifications, mutations, or fusions occur in various cancer cell types." @default.